 Interleukin-1
"Interleukin-1" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A soluble factor produced by MONOCYTES; MACROPHAGES, and other cells which activates T-lymphocytes and potentiates their response to mitogens or antigens. Interleukin-1 is a general term refers to either of the two distinct proteins, INTERLEUKIN-1ALPHA and INTERLEUKIN-1BETA. The biological effects of IL-1 include the ability to replace macrophage requirements for T-cell activation.
| Descriptor ID |
D007375
|
| MeSH Number(s) |
D12.644.276.374.465.501 D12.644.276.374.500.400 D12.776.467.374.465.501 D12.776.467.374.500.400 D23.529.374.465.501 D23.529.374.500.400
|
| Concept/Terms |
Interleukin-1- Interleukin-1
- Interleukin 1
- IL-1
- T Helper Factor
- Lymphocyte-Activating Factor
- Lymphocyte Activating Factor
- Macrophage Cell Factor
- Epidermal Cell Derived Thymocyte-Activating Factor
- Epidermal Cell Derived Thymocyte Activating Factor
- Interleukin I
|
Below are MeSH descriptors whose meaning is more general than "Interleukin-1".
Below are MeSH descriptors whose meaning is more specific than "Interleukin-1".
This graph shows the total number of publications written about "Interleukin-1" by people in this website by year, and whether "Interleukin-1" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1981 | 2 | 4 | 6 | | 1982 | 5 | 4 | 9 | | 1983 | 7 | 0 | 7 | | 1984 | 20 | 4 | 24 | | 1985 | 17 | 2 | 19 | | 1986 | 39 | 5 | 44 | | 1987 | 53 | 4 | 57 | | 1988 | 42 | 6 | 48 | | 1989 | 45 | 8 | 53 | | 1990 | 37 | 4 | 41 | | 1991 | 27 | 7 | 34 | | 1992 | 27 | 10 | 37 | | 1993 | 28 | 14 | 42 | | 1994 | 36 | 6 | 42 | | 1995 | 19 | 15 | 34 | | 1996 | 16 | 8 | 24 | | 1997 | 16 | 6 | 22 | | 1998 | 18 | 8 | 26 | | 1999 | 19 | 10 | 29 | | 2000 | 18 | 11 | 29 | | 2001 | 10 | 11 | 21 | | 2002 | 5 | 14 | 19 | | 2003 | 14 | 10 | 24 | | 2004 | 19 | 11 | 30 | | 2005 | 8 | 10 | 18 | | 2006 | 6 | 6 | 12 | | 2007 | 3 | 1 | 4 | | 2008 | 1 | 2 | 3 | | 2009 | 6 | 2 | 8 | | 2010 | 7 | 5 | 12 | | 2011 | 5 | 4 | 9 | | 2012 | 2 | 5 | 7 | | 2013 | 5 | 2 | 7 | | 2014 | 8 | 3 | 11 | | 2015 | 10 | 3 | 13 | | 2016 | 8 | 1 | 9 | | 2017 | 6 | 1 | 7 |
To return to the timeline, click here.
Below are the most recent publications written about "Interleukin-1" by people in Profiles.
-
Nowak KL, Hung A, Ikizler TA, Farmer-Bailey H, Salas-Cruz N, Sarkar S, Hoofnagle A, You Z, Chonchol M. Interleukin-1 inhibition, chronic kidney disease-mineral and bone disorder, and physical function?. Clin Nephrol. 2017 Sep; 88(9):132-143.
-
Hoeke G, Khedoe PPSJ, van Diepen JA, Pike-Overzet K, van de Ven B, Vazirpanah N, Mol I, Hiemstra PS, Staal FJT, Stienstra R, Netea MG, Dinarello CA, Rensen PCN, Berbée JFP. The Effects of Selective Hematopoietic Expression of Human IL-37 on Systemic Inflammation and Atherosclerosis in LDLr-Deficient Mice. Int J Mol Sci. 2017 Aug 09; 18(8).
-
Carey A, Edwards DK, Eide CA, Newell L, Traer E, Medeiros BC, Pollyea DA, Deininger MW, Collins RH, Tyner JW, Druker BJ, Bagby GC, McWeeney SK, Agarwal A. Identification of Interleukin-1 by Functional Screening as a Key Mediator of Cellular Expansion and Disease Progression in Acute Myeloid Leukemia. Cell Rep. 2017 03 28; 18(13):3204-3218.
-
Li J, Zhai Y, Ao L, Hui H, Fullerton DA, Dinarello CA, Meng X. Interleukin-37 suppresses the inflammatory response to protect cardiac function in old endotoxemic mice. Cytokine. 2017 07; 95:55-63.
-
Cavalli G, Justice JN, Boyle KE, D'Alessandro A, Eisenmesser EZ, Herrera JJ, Hansen KC, Nemkov T, Stienstra R, Garlanda C, Mantovani A, Seals DR, Dagna L, Joosten LA, Ballak DB, Dinarello CA. Interleukin 37 reverses the metabolic cost of inflammation, increases oxidative respiration, and improves exercise tolerance. Proc Natl Acad Sci U S A. 2017 02 28; 114(9):2313-2318.
-
Roerink ME, van der Schaaf ME, Dinarello CA, Knoop H, van der Meer JW. Interleukin-1 as a mediator of fatigue in disease: a narrative review. J Neuroinflammation. 2017 Jan 21; 14(1):16.
-
Liang K, Volk AG, Haug JS, Marshall SA, Woodfin AR, Bartom ET, Gilmore JM, Florens L, Washburn MP, Sullivan KD, Espinosa JM, Cannova J, Zhang J, Smith ER, Crispino JD, Shilatifard A. Therapeutic Targeting of MLL Degradation Pathways in MLL-Rearranged Leukemia. Cell. 2017 Jan 12; 168(1-2):59-72.e13.
-
Woulfe KC, Siomos AK, Nguyen H, SooHoo M, Galambos C, Stauffer BL, Sucharov C, Miyamoto S. Fibrosis and Fibrotic Gene Expression in Pediatric and Adult Patients With Idiopathic Dilated Cardiomyopathy. J Card Fail. 2017 Apr; 23(4):314-324.
-
Nowak KL, Chonchol M, Ikizler TA, Farmer-Bailey H, Salas N, Chaudhry R, Wang W, Smits G, Tengesdal I, Dinarello CA, Hung AM. IL-1 Inhibition and Vascular Function in CKD. J Am Soc Nephrol. 2017 Mar; 28(3):971-980.
-
Cavalli G, Koenders M, Kalabokis V, Kim J, Tan AC, Garlanda C, Mantovani A, Dagna L, Joosten LA, Dinarello CA. Treating experimental arthritis with the innate immune inhibitor interleukin-37 reduces joint and systemic inflammation. Rheumatology (Oxford). 2016 Dec; 55(12):2220-2229.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|